Canopy Growth Corp (TSE:WEED) (OTCMKTS:TWMJF) (FRA:11L1) lead the cannabis sector higher today, as two important catalysts helped fuel the rally. The strong price action was immediate and decisive, with the sector leader climbing right from the opening bell.
The first impetus was a full length documentary produced and aired by CNN yesterday, titled Weed 4: Pot vs. Pills. The special report was the fourth in a series which last aired in 2015 (Weed 3: The Marijuana Revolution). The high-profile documentary reflects favorably on cannabis consumption as a legitimate substitute for opioids for people seeking pain management solutions.
Of course, CNN’s report is nothing new or groundbreaking to investors in the space. However, for a sector in search of a compelling catalyst to fire up investors, the report hit the mark. Especially true considering sector price action had been grinding down on moribund volume recently. From that standpoint, the added media attention helped clear the decks of sellers and allow bulls to generate some breathing room. If marijuana consumption can cut into the pharmaceutical opioid market even moderately, Big Cannabis stands to gain billions in profits.
While the well-timed CNN piece helped flip cannabis investing sentiment for the time being, another catalyst also promoted investor participation.
Earlier this morning, it was reported that Canada’s biggest pension funds are backing pot stocks. Several large Canadian pension funds have entered the fray by making early investments in cannabis companies. This included the likes of provincial pension funds Alberta Investment Management Corp. (approx. $100 billion AUM) and British Columbia Investment Management Corp., who were among a list of around 50 investors who participated in Canopy Growth’s $200.7 million bought-deal financing in January. The list also includes Canada Post’s pension fund, which in 2016 had $23.1 billion under management.
Ultimately, when provincial crown corporations start entering the fray, legitimacy has essentially arrived. While some of the upcoming investment will no doubt be linked to forced indexing (Canopy Growth and Aurora Cannabis were both added to the S&P/TSX Composite Index this year), it’s likely some substantial stand-alone investment will take place. If and when pension funds start undertaking five-percent-plus positions in individual cannabis companies, investors will know validity of the highest magnitude has been obtained. Big Cannabis might as well be Molson Coors Brewing Company or Loblaw Companies from an investment prestige standpoint.
Looking at Canopy Growth specifically, price action was encouraging. While still lagging under its 3-month average, volume rang in a 4,341,591 shares, the most in two weeks. The stock closed above its 100-Day MA and slightly above the important 50-Day MA, where prices have grappled in the recent path. The price action is also notable as it moves the symmetrical triangle goalposts that much closer to resolution. Given the defined nature and still-strong volume profile of the technical pattern, we expect a major surge in the coming week(s).
Aurora Cannabis experienced much the same move, albeit with moderately less gusto. Unlike Canopy Growth, the company had two notable news items today.
First, a writer in the Australian Financial Review suggested that Aurora was preparing to acquire a cannabis licensee in Australia named Cann Group Limited. The speculation was that Aurora Cannabis—currently the largest shareholder of Cann Group—might make a play for a super-majority stake at $4.50/share.
Secondly, the company announced it had partnered up with Mitacs to fund a University of Alberta research program studying the health outcomes associated with cannabis use. The subsequent results are intended to be submitted for publication by an accredited journal. No financial commitment details were disclosed.
Although aggregate volume finished well below its 3-month average, shares traded hands at the most brisk pace since April 16. Unlike Canopy Growth, Aurora Cannabis did not experience a third power move higher at the close. It appears investors were content to hold serve after the on-open surge, which lasted until just after 11am.
Perhaps chart quality is the deciding factor here . Before Aurora Cannabis can get into stronger technical position, it needs get into striking distance of the 50 and 100-Day moving averages, which rest at $9.59 and $10.06 respectively. Despite today’s move, there’s still a long way to go.
Here were the rest of the sector numbers at-large:
|Company||Closing Price||Loss/Gain||% Loss/Gain||Volume|
|Canopy Growth Corporation||30.11||2.76||10.09%||4.34m|
|Emerald Health Therapeutics Inc.||4.65||0.25||5.68%||445.95k|
|The Hydropothecary Corporation||4.31||0.23||5.64%||2.47m|
|Aurora Cannabis Inc.||8.09||0.43||5.61%||8.93m|
|Namaste Technologies Inc||1.6||0.07||4.58%||3.46m|
|OrganiGram Holdings Inc||4.07||0.16||4.09%||453.60k|
|Cannabis Wheaton Income Corp.||1.59||0.05||3.25%||1.84m|
|THC Biomed Intl Ltd||1.28||0.03||2.40%||173.73k|
|CannTrust Holdings Inc.||6.98||0.15||2.20%||333.41k|
|Newstrike Resources Ltd.||1.03||0.02||1.98%||698.20k|
|Abcann Global Corporation||1.64||0.03||1.86%||585.35k|
|MYM Nutraceuticals Inc||1.73||0.03||1.76%||320.17k|
|Cannabix Technologies Inc||1.85||0.03||1.65%||240.92k|
|Cronos Group Inc.||6.91||0.11||1.62%||1.80m|
|Invictus MD Strategies Corp||1.75||0.01||0.57%||251.00k|
|Hiku Brands Company Ltd.||1.44||0||0.00%||669.10k|
|Maricann Group Inc.||1.6||0||0.00%||1.17m|
|The Supreme Cannabis Company Inc.||1.56||-0.01||-0.64%||441.08k|
|Isodiol International Inc.||0.8||-0.01||-1.23%||1.77m|
|CanniMed Therapeutics Inc.||28.5||-0.5||-1.72%||58.66k|
|InMed Pharmaceuticals Inc.||1.1||-0.02||-1.79%||353.43k|
Note: Mid/large cannabis companies noticeably outperformed small cap today. Perhaps this is in direct relation to the pension fund news described above.
Midas Letter is provided as a source of information only, and is in no way to be construed as investment advice. James West, the author and publisher of the Midas Letter, is not authorized to provide investor advice, and provides this information only to readers who are interested in knowing what he is investing in and how he reaches such decisions.
Investing in emerging public companies involves a high degree of risk and investors in such companies could lose all their money. Always consult a duly accredited investment professional in your jurisdiction prior to making any investment decision.
Midas Letter occasionally accepts fees for advertising and sponsorship from public companies featured on this site. James West and/or Midas Letter may also receive compensation from companies affiliated with companies featured on this site. James West and/or Midas Letter also invests in companies on this site and so readers should view all information on this site as biased.